According to the US Centers for Disease Control and Prevention, over 2 million health-related issues were reported in 2013, with 23,000 people dying as a result of drug-resistant bacteria. More than 450,000 new cases of multidrug-resistant TB were reported in the United States in 2012. The growing number of drug-resistant patients around the world necessitates the development of novel antibiotics to combat common infectious diseases. Peptides like Oxytocin, Cyclosporin, Salmon Calcitonin, Integrillin, and Zoladex are well-known and are leading the peptide therapies business in new directions around the world.
